Nuevolution’s present objectives are to develop several attractive small molecule programs up to a clinical Candidate or to an early clinical stage. We embrace partnerships to advance novel promising programs rapidly through clinical development to commercialization and provide treatment benefit for the patients.
Nuevolution has successfully applied its drug discovery platform to establish a portfolio of internal pipeline programs within oncology, immuno-oncology and inflammatory (autoimmune) diseases
Our current programs available for partnering are:
- RORγt – Orally available RORγt inverse agonists for inflammatory diseases
- BET-BRD – First-in-class BET domain selective bromodomain 1 inhibitors
- IL-17A – First-in-class IL17A small molecule (topical & systemic) program targeting inflammatory diseases
Further information on our pipeline projects is available in the pipeline section.
The Almirall and Nuevolution partnership is a global strategic collaboration focusing on the development and commercialization of Nuevolution’s novel RORgt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis. Both parties will work in this research collaboration towards to successful identification of additional RORgt inhibitors, where Almirall has an exclusive option for use within dermatology and where Nuevolution has optional use in areas outside the field of collaboration.